Detecting inducible clindamycin resistance means performing a double-disk diffusion test (the D-test) or an equivalent molecular assay, because routine clindamycin susceptibility testing alone misses isolates that carry an erm gene but appear susceptible in vitro. Standard disk diffusion and automated MIC panels can report clindamycin as susceptible while the isolate harbors inducible resistance that emerges during therapy. The D-test exposes that hidden phenotype by placing a clindamycin disk near an erythromycin disk and looking for blunting of the clindamycin zone.
The molecular mechanism behind the D-shape
Macrolide resistance in staphylococci and streptococci usually runs through one of two routes. The erm genes encode rRNA methylases that dimethylate adenine 2058 in the 23S rRNA subunit, blocking binding of macrolides, lincosamides, and streptogramin B. Because a single methylated rRNA operon can shut down multiple ribosomes, erm expression is often cooperative and can be switched on by exposure to a macrolide.
That switching is the whole point of the inducibility problem. In isolates with constitutive erm expression, clindamycin already tests resistant, so no D-test is needed. In isolates with inducible erm expression, the methylase gene is largely silent until an inducer — erythromycin is the classic one — binds and triggers translation of the methylase transcript. During the D-test, erythromycin diffuses outward from its disk and induces erm expression in nearby bacteria. Those induced organisms grow right up to the clindamycin disk edge, flattening the side of the zone that faces the erythromycin disk. The result is the characteristic D shape.
The msrA gene produces a different phenotype. It encodes an ATP-binding cassette efflux pump that exports 14- and 15-membered macrolides but not clindamycin or streptogramin B. msrA-positive staphylococci test resistant to erythromycin and susceptible to clindamycin, and they do not produce a D shape because the efflux pump does not touch clindamycin. Distinguishing erm from msrA matters clinically: msrA isolates can generally still be treated with clindamycin, whereas inducible erm isolates cannot.
Quantified context: why the phenotype is worth detecting
The prevalence of inducible clindamycin resistance varies enormously by geography, species, and setting. In Staphylococcus aureus, rates in the single digits to low double digits are common in many US and European hospital collections, while some Asian and Latin American centers report rates several times higher. In coagulase-negative staphylococci the proportion tends to be higher still. Among beta-hemolytic streptococci, inducible resistance is less frequent but well documented, particularly in Streptococcus agalactiae from certain populations.
The clinical stakes are concrete. Clindamycin is a first-line option for skin and soft tissue infections caused by methicillin-resistant S. aureus, for necrotizing fasciitis involving group A streptococci, and for penicillin-allergic patients with serious streptococcal disease. If an inducible erm isolate is treated with clindamycin, resistance can emerge during therapy and lead to treatment failure. That risk is the reason the Clinical and Laboratory Standards Institute requires D-testing when erythromycin is resistant and clindamycin is susceptible in staphylococci, and recommends it for beta-hemolytic streptococci as well [CLSI M100].
Timing matters for turnaround. Standard disk diffusion requires 16 to 18 hours of incubation for staphylococci and 20 to 24 hours for streptococci. Automated MIC panels typically report in 8 to 24 hours depending on the platform, but many do not perform induction testing unless specifically configured. Molecular assays for erm and msrA can return results within a few hours of a positive culture, but they add cost and require the laboratory to validate off-label or laboratory-developed tests.
Comparison of detection methods
| Method | What it detects | Typical turnaround | Strengths | Limitations |
|---|---|---|---|---|
| Disk diffusion D-test | Inducible erm phenotype | 16-24 hours | Low cost, widely available, direct phenotype | Requires careful disk spacing and reading; interpretive errors possible |
| Broth microdilution MIC | Constitutive resistance only | 16-24 hours | Quantitative, standardized | Does not reliably reveal inducibility |
| Automated susceptibility panel | Constitutive resistance only unless configured | 8-24 hours | Fast, integrated reporting | Default configuration often omits induction |
| PCR for erm and msrA | Genotype | 2-4 hours | Fast, distinguishes erm from msrA | Does not prove expression; requires validation |
| Inducible clindamycin resistance agar screen | Phenotype | 18-24 hours | Simple, can be batched | Less familiar to many technologists |
The table makes the tradeoff clear: phenotypic induction testing captures the clinically relevant behavior, while genotypic testing captures the gene but not its expression state. Neither is a substitute for the other in every situation.
Edge cases that break the simple algorithm
The D-test is not a universal rule, and several situations demand judgment. Inducible resistance can be missed if the erythromycin and clindamycin disks are placed too far apart. CLSI specifies a center-to-center distance of 15 to 26 mm for staphylococci, and technologists who use a different spacing may see a false-negative result. Overly heavy inoculum can also obscure the D shape.
False-negative D-test from excessive disk spacing or poor inoculum standardization. Constitutive resistance masked by a mixed population that appears inducible on first reading. msrA efflux mistaken for inducible erm if the D shape is over-interpreted. Beta-hemolytic streptococci with borderline zones that fall into no clear category. Isolates that lose erm expression on subculture and no longer demonstrate the phenotype. Automated panels that report clindamycin susceptible without any induction step.
A counterintuitive caveat deserves emphasis: a negative D-test does not guarantee that clindamycin will work. Rare isolates can carry erm genes that are not induced under test conditions, and some erm variants express at low levels that fail to produce a visible D shape. The D-test is a phenotype assay, and phenotypes are conditional on the test environment.
Misconceptions that persist in practice
The most common misconception is that a clindamycin-susceptible MIC rules out inducible resistance. It does not. Broth microdilution and most automated panels measure growth at a fixed clindamycin concentration, and inducible isolates grow normally in that well because the methylase has not been triggered. Only an induction step reveals the latent resistance.
A second misconception is that the D-test is only needed for MRSA. Inducible clindamycin resistance occurs in methicillin-susceptible S. aureus as well, and in coagulase-negative staphylococci. Skipping the test because the isolate is methicillin-susceptible can miss a clinically relevant phenotype.
A third misconception conflates genotype with phenotype. A positive erm PCR does not automatically mean clindamycin will fail, because some erm genes are expressed at low levels or are not inducible in that host. Conversely, a negative PCR does not fully exclude resistance if the assay does not cover all erm variants. The laboratory must interpret molecular results in the context of the phenotypic test and the clinical setting.
Practical actions for laboratories and clinicians
For laboratories, the workflow should start with a clear decision rule. When erythromycin is resistant and clindamycin is susceptible by disk diffusion in a staphylococcus, place the clindamycin disk 15 to 26 mm center-to-center from the erythromycin disk. Incubate per CLSI, read at 16 to 18 hours for staphylococci, and report inducible clindamycin resistance when any blunting of the clindamycin zone occurs. For beta-hemolytic streptococci, follow the current CLSI guidance for D-testing and interpret borderline zones conservatively.
Standardize disk spacing at every bench and document it in the procedure manual. Perform D-testing whenever erythromycin is resistant and clindamycin is susceptible in staphylococci. Confirm borderline or ambiguous D shapes with a second method or repeat testing. Report inducible resistance as resistant for clindamycin, not as an ambiguous comment. Consider erm and msrA PCR when rapid turnaround is needed and the assay is validated. Review automated panel configurations to ensure induction testing is not silently omitted.
For clinicians, the practical threshold is straightforward. If the laboratory reports inducible clindamycin resistance, do not use clindamycin for that isolate. If the D-test is negative, clindamycin remains an option subject to the usual clinical judgment. When the laboratory reports clindamycin susceptible without a documented D-test, ask whether induction testing was performed, particularly for staphylococci from serious infections.
Limitations and what the evidence cannot settle
Several questions remain open. The optimal D-test spacing for streptococci is less firmly established than for staphylococci, and some laboratories use modified distances. The clinical significance of low-level erm expression that produces a weak or absent D shape is uncertain. Molecular assays that detect erm and msrA are not universally standardized, and their predictive value for treatment failure has not been established in large prospective trials. Cost varies widely: disk-based D-testing adds little to routine susceptibility costs, while molecular testing can add a meaningful per-isolate charge depending on the platform and validation burden.
The most defensible conclusion is that detecting inducible clindamycin resistance requires an induction step, not just a susceptibility result. The D-test remains the reference phenotypic method, and its limitations are manageable when disk spacing, inoculum, and incubation are controlled. Molecular methods complement but do not replace the phenotype. Laboratories that skip induction testing and clinicians who treat a clindamycin-susceptible result as definitive are the two failure points that matter most.